An HLA-presented fragment of macrophage migration inhibitory factor is a therapeutic target for invasive breast cancer

Journal of Immunology

Volumn 186, Issue 11, 2011, Pages 6607-6616

  Hawkins, Oriana ^a   Verma, Bhavna ^b   Lightfoot, Stanley ^a   Jain, Rinki ^b   Rawat, Amit ^b   McNair, Sandy ^c   Caseltine, Shannon ^c   Mojsilovic, Aleksandar ^a   Gupta, Priyanka ^c   Neethling, Francisca ^c   Almanza, Othon ^d   Dooley, William ^a   Hildebrand, William ^a   Weidanz, Jon ^b,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Receptor Logic Inc   (United States)

^d Clinical Pathology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; MACROPHAGE MIGRATION INHIBITION FACTOR[19-27]; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INVASION; CELL SURFACE; CONTROLLED STUDY; EPITHELIUM CELL; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN TARGETING; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HLA-A ANTIGENS; HUMANS; KINETICS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, NUDE; PEPTIDES; PROGNOSIS; PROTEIN BINDING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958025265     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003995     Document Type: Article

References (49)

1. Valabrega, G., F. Montemurro, and M. Aglietta. 2007. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 18: 977-984.
2. Shastri, N., S. Schwab, and T. Serwold. 2002. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu. Rev. Immunol. 20: 463-493.
3. Brodsky, F. M., L. Lem, and P. A. Bresnahan. 1996. Antigen processing and presentation. Tissue Antigens 47: 464-471.
4. Alexander, R. B., F. Brady, M. S. Leffell, V. Tsai, and E. Celis. 1998. Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology 51: 150-157. (Pubitemid 28092528)
5. Weynants, P., J. Thonnard, M. Marchand, M. Delos, T. Boon, and P. G. Coulie. 1999. Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival. Am. J. Respir. Crit. Care Med. 159: 55-62.
6. Wolfel, T., J. Schneider, K. H. Meyer Zum Buschenfelde, H. G. Rammensee, O. Rotzschke, and K. Falk. 1994. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1. Int. J. Cancer 57: 413-418. (Pubitemid 24168618)
7. Traversari, C., P. van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176: 1453-1457.
8. Vonderheide, R. H., W. C. Hahn, J. L. Schultze, and L. M. Nadler. 1999. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10: 673-679.
9. Parkhurst, M. R., J. P. Riley, T. Igarashi, Y. Li, P. F. Robbins, and S. A. Rosenberg. 2004. Immunization of patients with the hTERT:540-548 peptide induces peptidereactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin. Cancer Res. 10: 4688-4698.
10. Rosenberg, S. A., and M. E. Dudley. 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21: 233-240.
11. + T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116: 1908-1918.
12. Bloom, B. R., and B. Bennett. 1966. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153: 80-82.
13. Calandra, T., J. Bernhagen, R. A. Mitchell, and R. Bucala. 1994. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179: 1895-1902.
14. Bacher, M., A. Meinhardt, H. Y. Lan, W. Mu, C. N. Metz, J. A. Chesney, T. Calandra, D. Gemsa, T. Donnelly, R. C. Atkins, and R. Bucala. 1997. Migration inhibitory factor expression in experimentally induced endotoxemia. Am. J. Pathol. 150: 235-246.
15. Bini, L., B. Magi, B. Marzocchi, F. Arcuri, S. Tripodi, M. Cintorino, J. C. Sanchez, S. Frutiger, G. Hughes, V. Pallini, et al. 1997. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18: 2832-2841. (Pubitemid 28059956)
16. Lue, H., M. Thiele, J. Franz, E. Dahl, S. Speckgens, L. Leng, G. Fingerle-Rowson, R. Bucala, B. Luscher, and J. Bernhagen. 2007. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26: 5046-5059. (Pubitemid 47206949)
17. Mitchell, R. A., H. Liao, J. Chesney, G. Fingerle-Rowson, J. Baugh, J. David, and R. Bucala. 2002. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. USA 99: 345-350.
18. Xu, X., B. Wang, C. Ye, C. Yao, Y. Lin, X. Huang, Y. Zhang, and S. Wang. 2008. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett. 261: 147-157. (Pubitemid 351253721)
19. Hagemann, T., J. Wilson, H. Kulbe, N. F. Li, D. A. Leinster, K. Charles, F. Klemm, T. Pukrop, C. Binder, and F. R. Balkwill. 2005. Macrophages induce invasiveness of epithelial cancer cells via NF-κB and JNK. J. Immunol. 175: 1197-1205.
20. Verjans, E., E. Noetzel, N. Bektas, A. K. Schutz, H. Lue, B. Lennartz, A. Hartmann, E. Dahl, and J. Bernhagen. 2009. Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer 9: 230.
21. McCoy, J. L., L. F. Jerome, J. H. Dean, G. B. Cannon, T. C. Alford, T. Doering, and R. B. Herberman. 1974. Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human breast carcinoma. J. Natl. Cancer Inst. 53: 11-17.
22. Meyer-Siegler, K. L., M. A. Bellino, and M. Tannenbaum. 2002. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 94: 1449-1456. (Pubitemid 34212639)
23. Yasasever, V., H. Camlica, D. Duranyildiz, H. Oguz, F. Tas, and N. Dalay. 2007. Macrophage migration inhibitory factor in cancer. Cancer Invest. 25: 715-719. (Pubitemid 350223175)
24. Jesneck, J. L., S. Mukherjee, Z. Yurkovetsky, M. Clyde, J. R. Marks, A. E. Lokshin, and J. Y. Lo. 2009. Do serum biomarkers really measure breast cancer? BMC Cancer 9: 164.
25. Bucala, R., and S. C. Donnelly. 2007. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity 26: 281-285.
26. Armstrong, M. E., M. Gantier, L. Li, W. Y. Chung, A. McCann, J. A. Baugh, and S. C. Donnelly. 2008. Small interfering RNAs induce macrophage migration inhibitory factor production and proliferation in breast cancer cells via a double-stranded RNA-dependent protein kinase-dependent mechanism. J. Immunol. 180: 7125-7133.
27. Ouertatani-Sakouhi, H., F. El-Turk, B. Fauvet, M. K. Cho, D. Pinar Karpinar, D. Le Roy, M. Dewor, T. Roger, J. Bernhagen, T. Calandra, et al. 2010. Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action. J. Biol. Chem. 285: 26581-26598.
28. Hawkins, O. E., R. S. Vangundy, A. M. Eckerd, W. Bardet, R. Buchli, J. A. Weidanz, and W. H. Hildebrand. 2008. Identification of breast cancer peptide epitopes presented by HLA-A*0201. J. Proteome Res. 7: 1445-1457.
29. Weidanz, J. A., T. Nguyen, T. Woodburn, F. A. Neethling, M. Chiriva-Internati, W. H. Hildebrand, and J. Lustgarten. 2006. Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J. Immunol. 177: 5088-5097. (Pubitemid 44527579)
30. Weidanz, J. A., P. Piazza, H. Hickman-Miller, D. Woodburn, T. Nguyen, A. Wahl, F. Neethling, M. Chiriva-Internati, C. R. Rinaldo, and W. H. Hildebrand. 2007. Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. J. Immunol. Methods 318: 47-58.
31. Corr, M., A. E. Slanetz, L. F. Boyd, M. T. Jelonek, S. Khilko, B. K. Al-Ramadi, Y. S. Kim, S. E. Maher, A. L. M. Bothwell, and D. H. Margulies. 1994. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science 265: 946-949.
32. Matsui, K., J. J. Boniface, P. Steffner, P. A. Reay, and M. M. Davis. 1994. Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness. Proc. Natl. Acad. Sci. USA 91: 12862-12866.
33. Saio, M., M. Teicher, G. Campbell, H. Feiner, Y. Delgado, and A. B. Frey. 2004. Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma. Clin. Exp. Metastasis 21: 243-249.
34. Gobbi, G., P. Mirandola, C. Micheloni, E. Solenghi, I. Sponzilli, M. Artico, G. Soda, G. Zanelli, G. Pelusi, T. Fiorini, et al. 2004. Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions. Int. J. Oncol. 25: 1625-1629.
35. Verma, B., R. Jain, S. Caseltine, A. Rennels, R. Bhattacharya, M. M. Markiewski, A. Rawat, F. Neethling, U. Bickel, and J. A. Weidanz. 2011. TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms. J. Immunol. 186: 3265-3276.
36. Gonzalez-Galarza, F. F., S. Christmas, D. Middleton, and A. R. Jones. 2011. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 39: D913-D919.
37. Brufsky, A. 2010. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am. J. Clin. Oncol. 33: 186-195.
38. Eheman, C. R., K. M. Shaw, A. B. Ryerson, J. W. Miller, U. A. Ajani, and M. C. White. 2009. The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004. Cancer Epidemiol. Biomarkers Prev. 18: 1763-1769.
39. Mallon, E., P. Osin, N. Nasiri, I. Blain, B. Howard, and B. Gusterson. 2000. The basic pathology of human breast cancer. J. Mammary Gland Biol. Neoplasia 5: 139-163. (Pubitemid 32045693)
40. Barnes, R., and S. Masood. 1990. Potential value of hormone receptor assay in carcinoma in situ of breast. Am. J. Clin. Pathol. 94: 533-537.
41. Bartkova, J., D. M. Barnes, R. R. Millis, and W. J. Gullick. 1990. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum. Pathol. 21: 1164-1167.
42. Ramachandra, S., L. Machin, S. Ashley, P. Monaghan, and B. A. Gusterson. 1990. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma: a detailed morphological analysis. J. Pathol. 161: 7-14.
43. Verma, B., F. A. Neethling, S. Caseltine, G. Fabrizio, S. Largo, J. A. Duty, P. Tabaczewski, and J. A. Weidanz. 2010. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. J. Immunol. 184: 2156-2165.
44. McMurtrey, C. P., A. Lelic, P. Piazza, A. K. Chakrabarti, E. J. Yablonsky, A. Wahl, W. Bardet, A. Eckerd, R. L. Cook, R. Hess, et al. 2008. Epitope discovery in West Nile virus infection: identification and immune recognition of viral epitopes. Proc. Natl. Acad. Sci. USA 105: 2981-2986.
45. Kim, S., L. Li, C. P. McMurtrey, W. H. Hildebrand, J. A. Weidanz, W. E. Gillanders, M. S. Diamond, and T. H. Hansen. 2010. Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J. Immunol. 184: 4423-4430.
46. Burgess, S. 2010. FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer. U.S. Food and Drug Administration, Silver Spring, MD.
47. Grieb, G., M. Merk, J. Bernhagen, and R. Bucala. 2010. Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect. 23: 257-264.
48. + T cells from melanoma patients reveals inefficient antigen processing. Eur. J. Immunol. 31: 2642-2651.
49. Lev, A., M. F. Princiotta, D. Zanker, K. Takeda, J. S. Gibbs, C. Kumagai, E. Waffarn, B. P. Dolan, A. Burgevin, P. Van Endert, et al. 2010. Compartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass action. Proc. Natl. Acad. Sci. USA 107: 6964-6969.